FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141...
Hence then, the article about fda accepts viatris supplemental new drug application for mr 141 phentolamine ophthalmic solution 0 75 for the treatment of presbyopia was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia )
Also on site :
- The Football Stars Missing This Summer's Cup Receive an Invitation from Ecuador
- World Cup 2026: New rules but VAR confusion – was diving decision right?
- Fatboy Slim entertains protesters outside Brighton station